Kenji Hyoudou

559 citations
15 papers · 491 indexed · h-index 14
Topics
Nanoparticle-Based Drug Delivery (5 papers)Nanoplatforms for cancer theranostics (5 papers)Immune Response and Inflammation (3 papers)
Partner nations
JapanUnited States

In The Last Decade

Kenji Hyoudou

15 papers receiving 488 citations

Peers

Kenji Hyoudou
Comparison fields: 5 of 81
  • Molecular Biology 262
  • Cancer Research 112
  • Oncology 88
  • Biomedical Engineering 82
  • Immunology 81
Replace Vinoth Prasanna Gunasekaran with:
Vinoth Prasanna Gunasekaran India
Niedzwiecki
Himani Sharma India
Alex Starr Israel
W. A. Dengler Germany
Dar-Shih Hsieh Taiwan
Forough Khadem Canada
Chunjie Wen China
Chuanke Zhao China
Kenji Hyoudou relative to Vinoth Prasanna Gunasekaran India Vinoth Prasanna Gunasekaran's profile →
Citations per field
00.5×
Vinoth Prasanna Gunasekaran · 1×
Citations per year

Countries citing papers authored by Kenji Hyoudou

Since Specialization
Citations

This map shows the geographic impact of Kenji Hyoudou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenji Hyoudou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenji Hyoudou more than expected).

Fields of papers citing papers by Kenji Hyoudou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenji Hyoudou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenji Hyoudou. The network helps show where Kenji Hyoudou may publish in the future.

Co-authorship network of co-authors of Kenji Hyoudou

This figure shows the co-authorship network connecting the top 25 collaborators of Kenji Hyoudou. A scholar is included among the top collaborators of Kenji Hyoudou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenji Hyoudou. Kenji Hyoudou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
#WorkIndexed citations
1 19
2 24
3 28
4 22
5 31
6 15
7 20
8 25
9 20
10 52
11 40
12 59
13 59
14 70
15 7

About Kenji Hyoudou

Kenji Hyoudou is a scholar working on Biomaterials, Cancer Research and Toxicology, having authored 15 papers that have together received 491 indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (5 papers), Nanoplatforms for cancer theranostics (5 papers) and Immune Response and Inflammation (3 papers). The work is most often cited by research in Cancer Research (112 citations), Toxicology (14 citations) and Biochemistry (24 citations). Kenji Hyoudou has collaborated with scholars based in Japan and United States. Frequent co-authors include Makiya Nishikawa, Mitsuru Hashida, Fumiyoshi Yamashita, Yuki Kobayashi, Yoshinobu Takakura, Yuki Kobayashi, Yuki Kobayashi, Emi Ishida, František Štaud and Yoshiyuki Yabe. Their work appears in journals such as Clinical Cancer Research, Free Radical Biology and Medicine and Journal of Controlled Release.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026